 Life Science Investor Mandates (Nov 5 - Nov. 11) |
| |
|
Seeking to In-License Clinical Stage Therapeutics in Neurology, Hepatology, and Gastroenterology
|
Seeking Medical Device, Diagnostics and HIT Investment Opportunities
|
|
Seeking Early Stage Therapeutics and Devices
|
|
Connected Devices Opportunities
|
|
Rising Opportunities in Precision Medicine
|
RESI Panel Announcement:
Biotech Angels Panel
|
RESI Panel Announcement: Medical Device Investors
|
|
|
|
When LSN first began a dialogue with life science investors three years ago, we encountered the common perception that diagnostics is a challenging area due to regulatory, reimbursement, and adoption issues. However, as LSN has tracked the diagnostic investment landscape over the last year, the mood change among investors is almost tangible. A large portion of their optimism is attributable to the promises of precision medicine.
Precision medicine, as defined by the National Institutes of Health, is an emerging approach for disease prevention and treatment that takes into account people's individual variations in genes, environment, and lifestyle. This year precision medicine has emerged as a vital sector of the industry, as evidence by a few healthy signs...
|
 |
|
Angel investors have been one of the first go-to investors as an incredibly important source of capital for fundraising entrepreneurs. They provide early stage companies not only with capital, but also with experience and professional knowledge due to their unique membership composition and investment focus.
Furthermore, there is a continuing trend of angels syndicating to participate in larger investment deals with angel investor rounds growing from $800K in 2014 to over $1M to date in 2015.
LSN has assembled accredited Angel investors particularly interested in biotech therapeutics for RESI San Francisco, occurring on January 12th. The Biotech Angels Panel will be moderated by Karl Handlesman, Founder of Codon Capital, and will be joined by:
- Amit Kumar, Member, Band of Angels
- Nola Masterson, Member, Science Futures
- John Reppas, Chair, Life Science Angels
- Eric Evans, Executive Committee, Mass Medical Angels
|
|
|
|
Medical technology represents a major segment of life science investment, with $2.7 billion in venture allocations going into devices and diagnostics in 2014. At LSN, we track over 700 investors who have an interest in development or clinical-stage medical devices. For RESI San Francisco, LSN has gathered a panel of experienced medical device investors to share their expertise and advice with medtech entrepreneurs.
Moderated by David Cassak, Managing Partner, Innovation In Medtech, our panelists are:
- Paul Grand, Managing Director, Research Corporation Technologies
- Randy Scott, Partner, HealthQuest Capital
- Mark Chin, Vice President, Longitude Capital
- Randy Barko, President & CEO, Ximedica
|
|
|
